Trials / Completed
CompletedNCT00109122
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
Detailed description
The duration of treatment is 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | zoster vaccine live (Oka/Merck) | |
| BIOLOGICAL | Comparator: placebo (unspecified) |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2003-02-01
- Completion
- 2006-07-01
- First posted
- 2005-04-25
- Last updated
- 2017-03-15
Source: ClinicalTrials.gov record NCT00109122. Inclusion in this directory is not an endorsement.